Table 1.
Demographics of the patients classified by the AKI development.
Fig 1.
The changes in urine neutrophil gelatinase-associated lipocalin (NGAL) and plasma NGAL serum creatinine, and cystatin C levels between AKI and non-AKI groups at different time points.
Table 2.
Changes in biomarker levels over time between the AKI and non-AKI group.
Fig 2.
AUC for plasma NGAL, urine NGAL, creatinine, and cystatin C at weeks when AKI was diagnosed.
Table 3.
Comparisons of the AUC between 1st and 2nd place of each biomarkers at each time period.
Table 4.
Cutoff value and sensitivity and specificity at the time of AKI diagnosis.